Cidara Therapeutics (NASDAQ:CDTX – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports. They presently have a $24.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 113.90% from the company’s current price.
Several other equities analysts have also recently issued reports on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Cidara Therapeutics in a research note on Wednesday, August 14th. StockNews.com raised shares of Cidara Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, September 13th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $25.00 price target on shares of Cidara Therapeutics in a report on Wednesday, August 14th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $29.67.
View Our Latest Research Report on Cidara Therapeutics
Cidara Therapeutics Price Performance
Cidara Therapeutics (NASDAQ:CDTX – Get Free Report) last posted its earnings results on Tuesday, August 13th. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.94) by $1.89. Cidara Therapeutics had a negative net margin of 289.05% and a negative return on equity of 109.89%. The firm had revenue of $0.30 million during the quarter. Equities analysts expect that Cidara Therapeutics will post -12.06 EPS for the current year.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Cidara Therapeutics stock. Tocqueville Asset Management L.P. increased its stake in shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX – Free Report) by 71.6% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 163,000 shares of the biotechnology company’s stock after buying an additional 68,000 shares during the period. Tocqueville Asset Management L.P. owned about 3.57% of Cidara Therapeutics worth $150,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 35.82% of the company’s stock.
About Cidara Therapeutics
Cidara Therapeutics, Inc, a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.
Recommended Stories
- Five stocks we like better than Cidara Therapeutics
- How to Invest in Small Cap Stocks
- Is CoStar Group Stock a Buy Before Earnings? Analysts Think So
- EV Stocks and How to Profit from Them
- 3 Stocks Driving the Shift to Nuclear Energy for AI Power
- How to Evaluate a Stock Before Buying
- Utilities Outperform in 2024: 3 Stocks to Keep on Your Radar
Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.